While there are a number of active movers on the stock market today, there are a few names, in particular, that stand out from the crowd – and for good reasons. Two of which include healthcare commercial stage company HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) and medical device company Aethlon Medical, Inc. (NASDAQ:AEMD)
The Companies
It’s true that HTG Molecular Diagnostics tends to be classified under the ‘Healthcare’ industry, while Aethlon Medical is classified under ‘Technology’, however, the latter is a San Diego-based company that develops medical devices which have the ability to pinpoint medical needs in an individual that have yet to be met, therefore, for the purpose of this article, I will be referring to both companies as if they are both options you can add to your healthcare investment portfolio.
What Happened Thursday?
As of this writing, Aethlon Medical is trading at $1.62, which puts the stock up $0.42, or 35.00%, while HTG Molecular Diagnostics is trading at $3.14, putting the stock up $0.85, or 36.92%.
The reason? While there doesn’t seem to be any recent news from Aethlon that would explain the more than 30% surge (who’s complaining?), HTC Molecular reported its preliminary Q4 financial results as well as provided its full-year 2018 revenue goals on Thursday, which would explain the increase.
HTG Molecular Diagnostics
Under the leadership of Timothy B. Johnson (CEO), and John. L. Lubniewski (CBO), HTG Molecular Diagnostics provides both instruments and services for molecular profiling applications. This application has become increasingly popular lately, which might explain why the company reported the results that it did.
Here’s what we know:
– HTG forecasts total revenue for Q4 of 2017 to come in between the range of $6.9 million and $7.2 million. As a point of reference, this estimate means that the company could see a 373% to 394% increase from Q4 in 2016.
– For the full year of 2017, total revenue for HTG Molecular is forecasted to come in between the range of $13.8 million and $14.1 million.
– According to the Tucson, Arizona-based company, collaboration revenue was the reason behind the increase in Q4 and full-year revenue.
According to Mr. Johnson, HTG believes that its momentum will continue as we move further into the new year, and if all goes as planned, the company should see continued revenue growth during 2018.
Keep in mind these are preliminary results that were presented based on the company’s management team’s initial revenue from its operations for the quarter.
Featured Image: twitter
